Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Stock analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Aldeyra Therapeutics in a research note issued to investors on Monday, May 19th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of ($0.23) for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at $1.90 EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at $0.85 EPS.

ALDX has been the subject of a number of other reports. BTIG Research dropped their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, April 7th. Wall Street Zen raised Aldeyra Therapeutics to a “sell” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock opened at $2.25 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The firm has a market capitalization of $134.77 million, a price-to-earnings ratio of -2.32 and a beta of 0.92. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20. The company has a 50 day moving average price of $3.20 and a 200 day moving average price of $4.65.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 2,822 shares during the last quarter. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at approximately $69,000. AlphaCentric Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at approximately $234,000. Boston Financial Mangement LLC acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth approximately $141,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth $3,628,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now owns 5,875,851 shares of the company’s stock, valued at $8,343,708.42. This trade represents a 36.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.60% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.